23.06.2010:
Scil
Proteins Pharma has
achieved validation of its proprietary Affilin® drug
discovery
platform in animals. The lead
product, SPVF 2801, an Affilin®
molecule for applications in solid tumors passed initial preclinical
studies
with excellent results. (pdf)
09.11.2009:
Bone marrow typing organised by Scil Proteins.
(pdf) (article in german)
14.09.2009:Scil Proteins signed an agreement with ipal GmbH and Charité University Hospital, Berlin for the purchase of the Tat Phage display technique.
(pdf)
18.08.2009:Dr. Henning Afflerbach was appointed as Chief Business Officer.
(pdf)
23.06.2009: Frank Ubags is appointed as financial director of Scil Proteins GmbH and Scil Proteins Production GmbH.
(pdf)
28.06.2009:Scil Proteins Production GmbH, the manufacturing site for Scil Proteins GmbH, has received the GMP certificate from the German regulatory authority of Saxony-Anhalt for the production of drug substances of microbiological origin.
(pdf)
01.02.2009:Scil Proteins receives 1,6 M€ grant to intensify research on the diagnosis and treatment of liver fibrosis.
(pdf)
24.06.2008:Scil Proteins Production GmbH announces the closing of a protein production deal with Swiss pharmaceutical firm Roche.
(pdf)
19.07.2006:
Scil Proteins and Cambridge Antibody Technology (CAT)
sign crosslicense
agreement in the field of Affilin® technology and ribosome display.
(pdf)
18.05.2006:Scil Proteins receives significant funding to strengthen in-house oncology programm.
(pdf) 
